Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors

Antiviral Therapy

Volumn 9, Issue 1, 2004, Pages 37-45

  Lanier, E Randall ^a   Ait Khaled, Mounir ^b   Scott, Janna ^a   Stone, Chris ^b   Melby, Thomas ^c   Sturge, Glenn ^a   St Clair, Marty ^a   Steel, Helen ^b   Hetherington, Seth ^a   Pearce, Gillian ^b   Spreen, William ^a   Lafon, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

^b Trimeris ^*

^c Trimeris Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TYPING; WILD TYPE;

EID: 12144290105     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellman NS & Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine 2002; 347:385-394.
2. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain P, Mantagne N, Schapiro JM, Boucher CAB & Dellamonica P. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradept study: week 48 follow-up. Antiviral Therapy 2000; 5:65-70.
3. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JPA, Merigan TC & the CPCRA 046 Study Team. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-F93.
4. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B & Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
5. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F & Girard PM. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
6. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R & De Luca A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-379.
7. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK & Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recommendations & Reports 2002; 51:1-55.
8. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases 2003; 37:113-128.
9. Daluge S, Good S, Faletto M, Miller W, St Clair M, Boone L, Tisdale M, Parry N, Reardon J, Dornsife R, Averett D & Krenitsky T. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrobial Agents & Chemotherapy 1997; 41:1082-1093.
10. Tisdale M, Alnadaf T & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41:1094-1098.
11. St. Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD & Larder BA. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
12. Gu Z, Gao Q, Li X, Parniak MA & Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine. Journal of Virology 1992; 66:7128-7135.
13. Zhang D, Caliendo A, Eron J, DeVore K, Kaplan J, Hirsch M & D'Aquila R. Resistance to 2′, 3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 1994; 38:282-287.
14. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T & Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 or 2 years. Antimicrobial Agents & Chemotherapy 1997; 41:757-762.
15. Tisdale M, Kemp SD, Parry NR & Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:5653-5666.
16. Gao Q, Gu Z, Parniak M, Cameron J, Cammack N, Boucher C & Wainberg M. The same mutation that encodes low-level human immunodeficiency type I resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′, 3′-dideoxy-3′-thiacytidine. Antimicrobial Agents & Chemotherapy 1993; 37:1390-1392.
17. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10:975-981.
18. Harrigan PR, Stone C, Griffin P, Najera I, Bloor S, Kemp S, Tisdale M, Larder B & the CNA2001 Investigative Group. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. Journal of Infectious Diseases 2000; 181:912-920.
19. Miller V & Larder B. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Therapy 2001; 6(Suppl. 3):25-44.
20. Lanier ER, Scott J, Ait-Khaled M, Craig C, Alcorn T, Irlbeck D, Gerondelis P, Burgess R & Underwood M. Prevalence of mutations associated with resistance to antiretroviral therapy from 1999-2002. 10th Conference on Retroviruses & Opportunistic Infections. Boston, Mass., USA, February 2003. Abstract 635.
21. Margot N, Isaacson E, McGowan I, Cheng A, Schooley R & Miller M. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 14:1227-1235.
22. Miller M, Margot N, Hertogs K, Larder B & Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001; 20:1025-1028.
23. Hertogs K, De Béhune M, Miller V, Ivens T, Schel P, van Cauwenberge A, van den Eynde C, van Gerwen V, Azjin H, van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B & Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type I isolates from patients treated with antiretroviral drugs. Antimicrobial Agents & Chemotherapy 1998; 42:269-276.
24. Petropoulos C, Parkin N, Limoli K, Lie Y, Wrin T, Huang W, Tian H, Smith D, Winslow G, Capon D & Whitcomb J. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 2000; 44:920-928.
25. Hosmer D & Lemeshow S. Applied Logistic Regression. 1989. New York, NY: John Wiley & Sons, Inc.
26. Hawkins D & Kass G. Automatic interaction detection. In: Topics in Applied Multivariate Analysis, 1982; pp. 269-302. Edited by D Hawkins. Cambridge: Cambridge University Press.
27. Breiman L, Freedman J & Olshen R. Classification and Regression Trees. 1984. New York, NY: Chapman & Hall.
28. Brun-Vezinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D & the Narval (ANRS 088) Study Group. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003; 17:1795-1802.